COSCIENS Biopharma Inc. is making waves on the TSX with a notable increase in its stock price.
COSCIENS Biopharma Inc. (CSCI.TO) is rising today, reflecting a positive shift in investor sentiment. The stock has seen a gain of 1.84%, bringing its current price to CA$7.20. With a market cap of approximately CA$7.5 million, the company is capturing attention in the biotech sector.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
COSCIENS Biopharma Inc.
CSCI.TO
CSCI.TO
COSCIENS Biopharma Inc.
WealthAwesomeMarket cap
$7.54M
52W high
$14.80
52W low
$1.10
1W change
-10.51%
Beta
1.89
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CSCI's historical volatility
30-Day Vol
574.5%
Annualized
90-Day Vol
353.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$8.45
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$7.50 | C$1.03 – C$54.47 |
| 60 trading days | C$7.96 | C$0.48 – C$131.41 |
| 90 trading days | C$8.45 | C$0.27 – C$261.89 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors are likely encouraged by the stock's upward movement, suggesting potential confidence in COSCIENS Biopharma's future prospects.
1.84% Gain Today
COSCIENS Biopharma's stock has risen by 1.84%, reflecting positive market sentiment.
Bull case
The recent increase in stock price may show that investors are feeling more confident. This could be driven by the company’s strategic initiatives and ongoing developments in its biopharmaceutical projects.
Bear case
Despite today’s gain, the lack of recent news or significant announcements might lead to some volatility. Investors could remain cautious about the company’s long-term performance.
Market Performance Overview
Advertisement
COSCIENS Biopharma Inc. is experiencing a notable rise in its stock price today, increasing by 1.84%. This uptick brings the stock to CA$7.20, indicating a positive trend for the company. Investors seem to be responding favorably, as the market cap hovers around CA$7.5 million, reflecting a growing interest in the biotech sector.
Investor Sentiment and Future Outlook
The current gain in COSCIENS Biopharma's stock price could signal a shift in investor sentiment, likely driven by the company's ongoing projects and strategic plans. While there are no recent announcements to support this rise, the increase suggests that investors are optimistic about the company's future. However, caution is advised, as the absence of concrete news could lead to fluctuations in the stock's performance.
Key Metrics at a Glance
With a profit margin of 50.68% and no current dividend yield, COSCIENS Biopharma's financial metrics present a mixed picture for investors. The P/E ratio remains unavailable, indicating that the company may still be in its growth phase. As investors consider their positions, these metrics will be crucial in assessing the company's long-term viability.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
